Asia Pacific Insulin Market Review to 2018
Transition from Human Insulin to Analog Insulin
Region:Asia
Product Code:KR246
September 2014
146
About the Report
The industry research publication titled ‘Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin’ presents a comprehensive analysis of market size by value of major types of insulin consumed in Asia Pacific region. The report entails the market share analysis of major insulin brands in premix insulin, long acting and rapid acting insulin category and company profiles of major players in the insulin market in India, China and Japan. The future analysis has also been discussed in each market.
The worldwide prevalence of diabetes was estimated to be ~ million in 2013 and is expected to soar 55%, reaching to 591.1 million patients by 2035. The primary determinants of diabetes are the rapid epidemiological transition associated with changes in dietary patterns and decreased physical activity. Nearly 5.1 million deaths in the world occurred due to diabetes in 2013. Low and middle income countries are host to almost 80.0% of the total diabetic cases in the world. However, diabetes imposes unacceptably high human, social and economic costs on countries at all income levels. The disease is observed to be most prevalent in Asia Pacific that includes the fastest growing economies globally. China and India are representatives of the above mentioned fact and have the highest number of people with diabetes in the world.
Since the Asian countries reside majorly in the middle income group, diagnosis and treatment of does not reach to a large part of the population. Lack of awareness and affordability are the biggest hindrances to curbing diabetes in the region. Nevertheless, due to increasing level of education and consciousness in the Asian countries, people are gradually paying more attention to diabetes care and diagnosis.
The world’s largest diabetic population resides in Asia Pacific due to which the demand for insulin is on a constant rise. Japan, China and India are the important markets in the region. The revenue generated by the insulin market in Asia Pacific in 2013 was estimated to be USD ~ million and registered a CAGR of ~% during 2008-2013. Japan adds the highest value to the regional market through the sale of high priced premium products. However, China is set to become the largest contributing market in the near future.
The global insulin market is distinctively dominated by 3 companies, namely Novo Nordisk from Denmark, Eli Lilly from the US and France’s Sanofi Aventis. A cumulative average of ~% of the market in every country is captured by these three companies. Regional players such as Biocon and Wockhardt in India and Shanghai Fosun Pharmaceuticals and Tonghua Dongbao in China have a minor stake in the countries’ respective insulin markets. Companies in the Asian region are consistently engaged in extensive R&D to introduce new products that are conducive to the local requirements. Furthermore, expiration of patents of several major brands of insulin in the recent future is expected to intensify competition in Asia Pacific. Launch of generic versions of the existing insulin brands in the coming years will lead to change in market shares of some of the leading insulin brands in the region.
Key Topics Covered in the Report
- The market size of Asia insulin market in terms of revenue
- Asian market segmentation by geographies covering China, India and Japan, by insulin replacement therapy and types of insulin
- Trends, growth drivers and challenges in Asia insulin market
- Product Pipeline of major insulin companies
- Future outlook and projections of the insulin market in Asia
- India insulin market size, segmentation by insulin replacement therapy and types of insulin, pricing scenario, trends, growth drivers and issues, market share of major companies in the market
- China insulin market size, segmentation by insulin replacement therapy and types of insulin, trends and growth drivers, market share of major companies in the market
- Government regulations and support schemes in India and China insulin market
- Japan insulin market size, segmentation by insulin replacement therapy and types of insulin, trends and growth drivers, market share of major companies in the market
- Profiles of major companies in India, China and Japan insulin market
- Future Outlook and macroeconomic factors in insulin market in China, India and Japan
Products
Insulin, Human Insulin, Analog Insulin, Premix, Rapid Acting, Long Acting, diabetes, Market Size, Market Share, Price of Insulin, diabetic population
Companies
Novo Nordisk India Private Limited, Eli Lilly and Company India Private Limited, Sanofi India Limited, Biocon Limited, Wockhardt Limited, Novo Nordisk (China) Pharmaceutical Company Limited, Eli Lilly and Company, Sanofi China, BJ Ganli Pharmaceuticals
Table of Contents
1. Asia Pacific Insulin Market Introduction
1.1. Asia Pacific Insulin Market Value Chain
1.2. Asia Pacific Insulin Market Size by Value, 2008-2013
1.3. Asia Pacific Insulin Market Segmentation, 2008-2013
1.3.1. By Geography, 2008-2013
1.3.2. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2013
1.3.3. By Types of Insulin (Premix, Rapid Acting, Long Acting), 2013
1.4. New Product Development By Major Insulin Companies
1.5. Trends and Developments in Asia Pacific Insulin Market
Monopoly of Foreign Brands
Phasing Out of Human Insulin
1.6. Growth Drivers and Challenges in Asia Pacific Insulin Market
Shift from Human Insulin to Analog Insulin
Rising Prevalence of Diabetes
Increasing Diabetes Care Expenditure
Low Affordability
Lack of Awareness
1.7. SWOT Analysis of Asia Insulin Market
1.8. Asia Pacific Insulin Market Future Outlook and Projections, 2014-2018
1.8.1. By Geography, 2014-2018
2. India Insulin Market Introduction
2.1. India Insulin Market Size, FY’2008-FY’2013
2.2. India Insulin Market Segmentation, FY’2008-FY’2013
2.2.1. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), FY’2008-FY’2013
2.2.2. By Types of Insulin (Premix, Rapid Acting, long Acting), FY’2008-FY’2013
2.2.3. Usage by Type of Diabetes, FY’2008-FY’2013
2.3. Government Regulations and Support Schemes in India Insulin Market
2.3.1. National Pharmaceutical Pricing Authority (NPPA)
Implications of Pricing Limits by NPPA
2.3.2. National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS)
2.4. Pricing Scenario in India Insulin Market
2.5. Trends and Developments in India Insulin Market
Price Gap Between Foreign and Domestic Insulin Brands
Shift of Diabetes to Young Age Group
Strategic Alliances in India Insulin Market
2.6. Growth Drivers and Challenges in India Insulin Market
Increasing Diabetic Population
Increasing Expenditure on Diabetes Care
Exchange Rate Fluctuation
2.7. Market Share of Major Companies in India Insulin Market, FY’2013
2.7.1. By Type of Insulin, FY’2013
2.7.1.1. By Premix Insulin, FY’2013
2.7.1.2. By Long Acting Insulin, FY’2013
2.7.1.3. By Rapid Acting Insulin, FY’2013
2.8. Company Profiles of Major Players in India Insulin Market
2.8.1. Novo Nordisk India Pvt. Ltd
2.8.1.1. Company Overview
2.8.1.2. Business Strategies
Market Expansion Through Spreading Awareness
Strengthening Research and Development (R&D) Activities
2.8.1.3. Competitive Standing
2.8.2. Eli Lilly and Company India Pvt. Ltd.
2.8.2.1. Company Overview
2.8.2.2. Business Strategies
Focus on Increasing R&D Investment in India
Concentration Towards the Diabetes Care Segment
2.8.2.3. Competitive Standing
2.8.3. Sanofi India Ltd.
2.8.3.1. Company Overview
2.8.3.2. Business Strategies
Commence Insulin Production in India
Product Innovation
Patient Awareness Programs
2.8.3.3. Competitive Standing
2.8.4. Biocon Ltd.
2.8.4.1. Company Overview
2.8.4.2. Competitive Standing
2.8.5. Wockhardt Ltd.
2.8.5.1. Company Overview
2.8.5.2. Competitive Standing
2.9. India Insulin Market Future Outlook and Projections, 2014-2018
2.9.1. By Insulin Replacement Therapy (Human Insulin and Analog Insulin, FY’2014-FY’2018
2.9.2. Cause and Effect Relationship Between Dependable and Independent Variable Factors prevailing in India Insulin Market
2.10. Macroeconomic Factors in India Insulin Market, 2008-2018
2.10.1. Diabetic Population in India, 2008-2018
2.10.2. India Government Spending on Healthcare, FY’2008-FY’2018
2.10.3. India Consumer Spending on Healthcare, FY’2008-FY’2018
2.10.4. India Personal Disposable Income, FY’2008-FY’2018
3. China Insulin Market Introduction
3.1. China Insulin Market Size by Sales Value and Volume, 2008-2013
3.2. China Insulin Market Segmentation, 2008-2013
3.2.1. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2008-2013
3.2.2. By Types of Insulin (Premix, Long Acting, Rapid Acting)
3.2.2.1. By Consumption Volume, 2008-2013
3.2.2.2. By Revenue, 2008-2013
3.2.3. Usage by Type of Diabetes, 2013
3.3. Government Regulations and Support Schemes for China Insulin Market
Drug Licensing Process
China National Plan for Chronic Disease Prevention and Treatment (2012-15)
Healthcare Reforms in China
3.4. Trends and Developments in China Insulin Market
Increasing Investment by Multinational Companies
Patent Expiry for Major Insulin Brands in China
3.5. Growth Drivers in China Insulin Market
Aging Population in China
Government Support for the Insulin Market in China
3.6. Market Shares of Major Companies in China Insulin Market
3.6.1. By Revenue, 2013
3.6.2. By Volume, 2010-2013
3.6.3. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2013
3.6.3.1. By Human Insulin, 2010 and 2013
3.6.3.2. By Analog Insulin, 2013
3.6.4. By Type of Insulin, 2013
3.6.4.1. By Premix Insulin, 2013
3.6.4.2. By Long Acting Insulin, 2013
3.6.4.3. By Rapid Acting Insulin, 2013
3.7. Company Profiles of major Players in China Insulin Market
3.7.1. Novo Nordisk (China) Pharmaceutical Co. Ltd.
3.7.1.1. Company Overview
3.7.1.2. Business Strategies
Increasing Diabetes Care Awareness
Strengthening Manufacturing and R&D Activities
3.7.1.3. Competitive Standing
3.7.2. Eli Lilly and Company
3.7.2.1. Company Overview
3.7.2.2. Business Strategies
Expanding Supply Chain and Distribution Through Local Distribution Partners
3.7.2.3. Competitive Standing
3.7.3. Sanofi China
3.7.3.1. Company Overview
3.7.3.2. Competitive Standing
3.7.4. Other Companies in China Insulin Market
3.7.4.1. BJ Ganli Pharmaceuticals
Company Overview
Competitive Standing
3.7.4.2. Tonghua Dongbao Pharmaceutical Co. Ltd.
Company Overview
Competitive Standing
3.8. China Insulin Market Future Outlook and Projections, 2014-2018
3.8.1. By Insulin Replacement Therapy, 2014-2018
3.8.2. By Type of Insulin, 2014-2018
3.8.3. Cause and Effect Relationship Between Dependable and Independent Variable Factors prevailing in India Insulin Market
3.9. Macroeconomic Factors in China Insulin Market, 2008-2018
3.9.1. Diabetic Population in China, 2008-2018
3.9.2. China Government Spending on Healthcare, 2008-2018
3.9.3. China Per Capita Expenditure on Healthcare, 2008-2018
3.9.4. China Personal Disposable Income, 2008-2018
4. Japan Insulin Market Introduction
4.1. Japan Insulin Market Size by Sales Value and Volume, 2008-2013
4.2. Japan Insulin Market Segmentation, 2008-2013
4.2.1. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2013
4.2.2. By Type of Insulin (Premix, Rapid Acting, Long Acting), 2008-2013
4.2.2.1. By Consumption Volume, 2008-2013
4.2.2.2. By Revenue, 2008-2013
4.3. Trends and Developments in Japan Insulin Market
Larger Proportion of Type 2 Diabetes Population
Patent Expiry for Major Insulin Brands in Japan
4.4. Growth Drivers and Challenges in Japan Insulin Market
Increasing Proportion of Ageing Population
Weakening of the Japanese Currency
4.5. Market Share of Major Companies in Japan Insulin Market, 2013
4.6. Competitive Landscape of Major Players in Japan Insulin Market
4.7. Japan Insulin Market Future Outlook and Projections, 2014-2018
4.7.1. Cause and Effect Relationship Between Dependable and Independent Variable Factors prevailing in Japan Insulin Market
4.8. Macroeconomic Factors in Japan Insulin Market, 2008-2018
4.8.1. Diabetic Population in Japan, 2008-2018
4.8.2. Japan Healthcare Expenditure, 2008-2018
4.8.3. Japan Disposable Income, 2008-2018
5. Appendix
5.1. Market Definitions
5.2. Abbreviations
5.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Final Conclusion
5.4. Disclaimer
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.